Catalent, Inc. (CTLT)

40.15 +1.30 (+3.35%) At close: 04:00PM EST

Catalent, Inc.

14 Schoolhouse Road
Somerset, NJ 08873
United States
732 537 6200
https://www.catalent.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 18,000

Key executives

Name	Title	Pay	Exercised	Year born
Mr. John J. Greisch M.B.A.	Executive Chairman of the Board	125k	N/A	1955
Mr. Alessandro Maselli	President, CEO & Director	1.53M	N/A	1972
Dr. Aristippos Gennadios Ph.D.	Group President of Pharma & Consumer Health Segment	1.13M	N/A	1966
Mr. Matti M. Masanovich	Senior VP & CFO	N/A	N/A	1972
Ms. Karen Murphy Santiago	VP & Chief Accounting Office	N/A	N/A	1971
Mr. Charles Lickfold	Senior VP & Chief Information Officer	N/A	N/A	1974
Mr. Paul Surdez	Vice President of Investor Relations	N/A	N/A	N/A
Mr. Joseph A. Ferraro J.D.	Senior VP, General Counsel, Chief Compliance Officer & Secretary	N/A	N/A	1979
Mr. Michael J. Grippo	Senior Vice President of Strategy & Corporate Development	N/A	N/A	1969
Ms. Lisa Evoli	Senior VP & Chief Human Resources Officer	N/A	N/A	1970

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics, and cell and gene therapies in clinical trials. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply services. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey.

Corporate governance

Catalent, Inc.’s ISS governance QualityScore as of 1 December 2023 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder rights: 6; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.